Effect of furosemide on angiotensin II-mediated prostaglandin I2 production in hypertensive subjects
Tóm tắt
The role of angiotensin II (AII) in Prostaglandin I2 (PGI2) production following furosemide has been examined in a placebo-controlled, cross-over study. Furosemide 20 mg was injected intravenously in eight hypertensive subjects already treated with oral captopril 25 mg or a matching placebo. Urinary excretion of 6-keto-PGF1α (a metabolite of PGI2) and PGE2, PRA and AII was increased following furosemide without captopril pretreatment. The rises in urinary 6-keto-PGF1α and PGE2, and plasma AII after furosemide were prevented by the captopril pretreatment. Urinary volume, sodium and furosemide were not affected by captopril. The data indicate that the effect of furosemide on PGI2 production, as reflected by the urinary excretion of 6-keto-PGF1α, was mediated by an action of AII.
Tài liệu tham khảo
Scherer B, Weber PC (1979) Time-dependent changes in prostaglandin excretion in response to furosemide in man. Clin Sci 56: 77–81
Mackay IG, Muir AL, Watson ML (1984) Contribution of prostaglandins to the systemic and renal vascular response to furosemide in normal man. Br J Clin Pharmacol 17: 513–519
Fujimura A, Ebihara A (1988) Role of angiotensin II in renal prostaglandin E2 production after furosemide administration. Hypertension 11: 491–494
Levenson DJ, Simmons CE, Brenner BM (1982) Arachidonic acid metabolism, prostaglandins and the kidney. Am J Med 72: 354–374
Stahl RAK, Paravicini M, Schollmeyer P (1984) Angiotensin II stimulation of prostaglandin E2 and 6-keto-F1α formation by isolated human glomeruli. Kidney Int 26: 30–34
Patrono C, Pugliese F, Ciabattoni G, Patrignani P (1982) Evidence for a direct stimulatory effect of prostacyclin on renin release in man. J Clin Invest 69: 231–239
Ikeda I, Iinuma K, Takai M (1982) Measurement of plasma renin activity by a simple solid phase radioimmunoassay. J Clin Endocrinol Metab 54: 423–428
Morimoto T, Aoyama M, Gotoh E, Shionoiri H (1983) A method of radioimmunoassay of plasma angiotensin II using florisil. Folia Endocrinol Jpn 59: 215–229
MacDougall ML, Shoeman DW, Azarnoff DL (1975) Separation and quantitative analysis of furosemide and 4-chloro-5-sulfamoylanthranilic acid (CSA) by high pressure liquid chromatography. Res Commun Chem Pathol Pharmacol 10: 285–292
Kawano K, Sugita M, Oka M, Tabata N (1987) A simple, rapid and simultaneous extraction of thromboxane B2, 6-keto-prostaglandin F and prostaglandin E2. Jpn J Inflammation 7: 511–515
Page IH (1987) The effects of angiotensin on renal circulation. In: Hypertension mechanisms. Grune and Stratton, Orlando, pp 389–393
Whittle BJR, Moncada S (1984) Prostacyclin-thromboxane interactions in hemostasis. In: Antonaccio M (ed) Cardiovascular pharmacology, 2nd edn. Raven Press, New York, pp 519–534
Brogden RN, Todd PA, Sorkin EM (1988) Captopril; an update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 36: 540–600
Van Hecken AM, Verbesselt R, Buntinx A, Cirillo VJ, De Schepper PJ (1987) Absence of a pharmacokinetic interaction between enalapril and furosemide. Br J Clin Pharmacol 23: 84–87
De Lepeleire I, Van Hecken A, Verbesselt R, Kaiser G, Barner A, Holmes I, De Schepper PJ (1988) Interaction between furosemide and the converting enzyme inhibitor benazepril in healthy volunteers. Eur J Clin Pharmacol 34: 465–468
Rakhit A, Kochak GM, Tipnis V, Hurley ME (1987) Inhibition of renal clearance of furosemide by pentopril, an angiotensin-converting enzyme inhibitor. Clin Pharmacol Ther 41: 580–586